GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoVista Innovative Therapies Inc (OTCPK:OVIT) » Definitions » Operating Income

OncoVista Innovative Therapies (OncoVista Innovative Therapies) Operating Income : $-3.40 Mil (TTM As of Sep. 2015)


View and export this data going back to 2005. Start your Free Trial

What is OncoVista Innovative Therapies Operating Income?

OncoVista Innovative Therapies's Operating Income for the three months ended in Sep. 2015 was $-0.32 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2015 was $-3.40 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. OncoVista Innovative Therapies's Operating Income for the three months ended in Sep. 2015 was $-0.32 Mil. OncoVista Innovative Therapies's Revenue for the three months ended in Sep. 2015 was $0.00 Mil. Therefore, OncoVista Innovative Therapies's Operating Margin % for the quarter that ended in Sep. 2015 was %.

OncoVista Innovative Therapies's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. OncoVista Innovative Therapies's annualized ROC % for the quarter that ended in Sep. 2015 was -58.99%. OncoVista Innovative Therapies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2015 was %.


OncoVista Innovative Therapies Operating Income Historical Data

The historical data trend for OncoVista Innovative Therapies's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoVista Innovative Therapies Operating Income Chart

OncoVista Innovative Therapies Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.40 -2.20 -1.98 -1.52 -2.55

OncoVista Innovative Therapies Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -1.73 -0.27 -1.09 -0.32

OncoVista Innovative Therapies Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoVista Innovative Therapies  (OTCPK:OVIT) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

OncoVista Innovative Therapies's annualized ROC % for the quarter that ended in Sep. 2015 is calculated as:

ROC % (Q: Sep. 2015 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2015 ) + Invested Capital (Q: Sep. 2015 ))/ count )
=-1.268 * ( 1 - 0% )/( (2.056 + 2.243)/ 2 )
=-1.268/2.1495
=-58.99 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2015) data.

2. Joel Greenblatt's definition of Return on Capital:

OncoVista Innovative Therapies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2015 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2015 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2015  Q: Sep. 2015
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.268/( ( (0 + max(-5.954, 0)) + (0 + max(-5.472, 0)) )/ 2 )
=-1.268/( ( 0 + 0 )/ 2 )
=-1.268/0
= %

where Working Capital is:

Working Capital(Q: Jun. 2015 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (4.309 + 0 + 1.645)
=-5.954

Working Capital(Q: Sep. 2015 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (3.708 + 0 + 1.764)
=-5.472

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2015) EBIT data.

3. Operating Income is also linked to Operating Margin %:

OncoVista Innovative Therapies's Operating Margin % for the quarter that ended in Sep. 2015 is calculated as:

Operating Margin %=Operating Income (Q: Sep. 2015 )/Revenue (Q: Sep. 2015 )
=-0.317/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


OncoVista Innovative Therapies Operating Income Related Terms

Thank you for viewing the detailed overview of OncoVista Innovative Therapies's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoVista Innovative Therapies (OncoVista Innovative Therapies) Business Description

Traded in Other Exchanges
N/A
Address
14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245
OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.
Executives
Alexander Ruckdaeschel director 123 EAST 83RD STREET, APT 3-B, NEW YORK NY 10028
Paul A Mieyal director C/O WEXFORD CAPITAL LP, 411 WEST PUTNAM AVE, SUITE 125, GREENWICH CT 06830
Charles E Davidson 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp 10 percent owner 777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Spectrum Trading Ltd 10 percent owner 411 WEST PUTNAM AVENUE, SUITE 125, GREENWICH CT 06830

OncoVista Innovative Therapies (OncoVista Innovative Therapies) Headlines

No Headlines